IceCure Medical (ICCM) announced it is in continued discussions with the U.S. FDA regarding its De Novo marketing authorization request for ProSense in early-stage low risk breast cancer with endocrine therapy. The company now expects the FDA’s marketing authorization decision to be reached after the first quarter of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s ProSense® Cryoablation Showcased at St. Gallen Breast Cancer Conference
- IceCure Medical Expands Global Patent Portfolio with New Cryogenic Pump Approval in China
- IceCure Medical receives Notice of Allowance from CNIPA
- IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study
- IceCure Medical Seeks Israeli Approval for Advanced Cryoablation System
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue